BN Business News
Add your company to Business Communicator →

Business · 08/06/2022Updated: 10/17/2026 · 1 min read

FDA Renews Pulmonary-Allergy Drugs Advisory Committee for 2 Years

Summary

The FDA has renewed the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on May 30, 2024.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →